Kerecis

Executive Summary

Kerecis is an Icelandic regenerative medicine company pioneering the use of intact fish skin from wild Atlantic cod as a natural scaffold for wound healing. Its proprietary platform, which minimally processes the fish skin, is designed to treat complex acute and chronic wounds, including diabetic ulcers, venous ulcers, trauma wounds, and surgical wounds. By leveraging a sustainable and biocompatible material, Kerecis positions itself as an innovative alternative to synthetic or cadaveric grafts, supporting tissue regeneration while reducing the risk of rejection. The company, founded in 2006, is privately held and headquartered in Reykjavik, Iceland. Kerecis has gained traction in the wound care market through clinical evidence and commercial partnerships, though it remains a relatively small player compared to established competitors like Mölnlycke or Smith+Nephew. The company's growth depends on expanding its regulatory approvals, particularly in the US, and scaling its manufacturing and sales capabilities. Upcoming catalysts include potential FDA clearance for a new wound type, expansion into European markets through direct sales or distributors, and possible strategic partnerships with larger medical device firms. With a unique value proposition around natural, fish-derived grafts, Kerecis is well-positioned to capture market share in the growing regenerative wound care segment, though execution risks remain.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for new wound indication (e.g., diabetic foot ulcers)70% success
• Q4 2026US commercial expansion through new distribution agreements60% success
• Q2 2026Publication of pivotal clinical trial results in peer-reviewed journal80% success